M	MCSA-5870	OMB No.: 2126-0006
	U.S. Department of Transportation Federal Motor Carrier Safety Administration	Expiration Date: 03/31/2025
Inc	Individual's Name:	
of i	of information subject to the requirements of the Paperwork Reduction Control Number for this information collection is 2126-0006. Public including the time for reviewing instructions, gathering the data nee	uired to respond to, nor shall a person be subject to a penalty for failure to comply with a collection Act unless that collection of information displays a current valid OMB Control Number. The OME reporting for this collection of information is estimated to be approximately 8 minutes per response ded, and completing and reviewing the collection of information. Send comments regarding this neluding suggestions for reducing this burden to: Information Collection Clearance Officer, Federa enue, SE, Washington, D.C. 20590.
	INSULIN-TREATED DI	ABETES MELLITUS ASSESSMENT FORM
N	Name:	DOB:
D	Driver's License Number (if applicable):	State:
Fe ha he tre	Federal Motor Carrier Safety Administration (FM has recently experienced a severe hypoglycemic e her ability based on his/her knowledge of the inditreating clinician is making a medical certification	mine whether he/she meets the physical qualification standards of the CSA) to operate a commercial motor vehicle or because the individual pisode. A treating clinician should complete this form to the best of his vidual's medical history. Completion of this form does not imply that a decision to qualify the individual to drive a commercial motor vehicle physically qualified to drive a commercial motor vehicle will be made by I Registry of Certified Medical Examiners.
	•	e professional who manages, and prescribes insulin for, treatment of the healthcare professional's applicable State licensing authority.
In	Instructions to the Individual:	
		ertification examination, the certified medical examiner must receive 45 calendar days after a treating clinician signs this form.
	When you are being evaluated after a severe hypogemedical examiner at your next medical certification	glycemic episode, you must retain this form and give it to the certified n examination.
In	Insulin-Treated Diabetes Mellitus Diagnosis	
1.	Date insulin use began:	
Bl	Blood Glucose Self-Monitoring Records	
2.	. Has the individual maintained at least the preceding 3 months of ongoing blood glucose self-monitoring records while being treated with insulin that are measured with an electronic glucometer that stores all readings, records the date and time of readings, and from which data can be electronically downloaded?	
	☐ Yes ☐ No	
3.	3. Has the individual provided at least the preced	ing 3 months of electronic self-monitoring records while being treated

with insulin from his/her glucometer to the treating clinician for review? Yes No

^{**}This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required to be maintained by regulatory requirements.**

MCSA-5870 OMB No.: 2126-0006 Expiration Date: 03/31/2025 **U.S. Department of Transportation Federal Motor Carrier Safety Administration** Individual's Name: _ If no, provide details: **Note:** The individual is not physically qualified to operate a commercial motor vehicle for up to the maximum 12-month period until he/she provides a treating clinician with at least the preceding 3 months of electronic blood glucose selfmonitoring records while being treated with insulin. At the certified medical examiner's discretion, the individual who does not possess at least the preceding 3 months of electronic blood glucose self-monitoring records while being treated with insulin may qualify to operate a commercial motor vehicle for up to but not more than 3 months. 4. How many times per day is the individual testing his/her blood glucose? 5. Is the individual compliant with blood glucose self-monitoring based on his/her specific treatment plan? Yes No Comments, if necessary: **Severe Hypoglycemic Episodes** 6. Has the individual experienced any severe hypoglycemic episodes within the preceding 3 months? FMCSA defines a severe hypoglycemic episode as one that requires the assistance of others, or results in loss of consciousness, seizure, or coma. Yes No If yes, provide date(s) of occurrence, whether the cause has been addressed, and associated details (attach additional pages as needed): Hemoglobin A1C (HbA1C) Measurements 7. Has the individual had HbA1C measured intermittently over the last 12 months, with the most recent measure within the preceding 3 months? No Yes If yes, attach the most recent result. **Diabetes Complications** 8. Does the individual have signs of diabetic complications or target organ damage? This information will be used by the certified medical examiner in determining whether the listed conditions would impair the individual's ability to safely operate a commercial motor vehicle. Renal disease/renal insufficiency (e.g., diabetic nephropathy, proteinuria, nephrotic syndrome)? Yes No

If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:

MCSA-5870 OMB No.: 2126-0006 Expiration Date: 03/31/2025 U.S. Department of Transportation

Federal Motor Carrier Safety Administration
Individual's Name:
b. Diabetic cardiovascular disease (e.g., coronary artery disease, hypertension, transient ischemic attack, stroke peripheral vascular disease)?
☐ Yes ☐ No
If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
c. Neurological disease/autonomic neuropathy (e.g., cardiovascular, gastrointestinal, genitourinary)?
☐ Yes ☐ No
If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
d. Peripheral neuropathy (e.g., sensory loss, decreased sensation, loss of vibratory sense, loss of position sense)? Yes No
If yes, provide the date of diagnosis, location, type of involvement, current treatment, and whether the condition is stable:
e. Lower limb (e.g., foot ulcers, amputated toes/foot, infection, gangrene)? Yes No If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
f. Other? (specify condition):
☐ Yes ☐ No
If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
Progressive Eye Diseases
9. Date of last comprehensive eye examination:
10. Has the individual been diagnosed with either severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy?
☐ Yes ☐ No
If yes, provide date of diagnosis:

³

^{**}This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required to be maintained by regulatory requirements.**

MCSA-5870 OMB No.: 2126-0006 Expiration Date: 03/31/2025

U.S. Department of Transportation Federal Motor Carrier Safety Administration	
Individual's Name:	
11. Has the individual been diagnosed with any o	other progressive eye disease(s) (e.g., macular edema, cataracts, glaucoma)?
If yes, specify the disease(s), provide the date	es of diagnoses, current treatment, and whether the condition is stable:
12. Additional Comments (attach additional pag	es as needed)
	ned above), that this individual maintains a stable insulin regimen and es mellitus, and that the information provided is true and correct to the
D. 4.	
Date	
Printed Name and Medical Credential	Signature
Professional License Number and State	
Phone Number	Email

⁴

^{**}This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required to be maintained by regulatory requirements.**